MedTrace Logo

Intraoperative Imaging of Pulmonary Adenocarcinoma

NCT02653612 · Status: WITHDRAWN · Phase: PHASE1 · Type: INTERVENTIONAL

Last updated 2018-03-02

No results posted yet for this study

Summary

The goal is to improve surgery by preventing tumor cells from being left behind at the time of surgery. This includes finding residual tumor cells in the wound after surgery.

Conditions

Interventions

DRUG

EC17 imaging contrast agent

This is an imaging agent to locate lung adenocarcinoma cancer cells during surgery

Sponsors & Collaborators

Principal Investigators

  • Colleen Gaughan, MD · Corporal Michael J. Crescenz VA Medical Center, Philadelphia, PA

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
99 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-01-01
Primary Completion
2018-02-26
Completion
2018-02-26
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02653612 on ClinicalTrials.gov